Christian Weber
Patrick Finzer- Institute of Medical Microbiology and Hospital Hygiene, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
Alzheimer`s disease (AD) is the most prevalent cause of dementia. It is often assumed that AD is caused by an aggregation of extracellular beta-amyloid and intracellular tau-protein, supported by a recent study showing reduced brain amyloid levels and reduced cognitive decline under treatment with a beta-amyloid-binding antibody. Confirmation of the importance of amyloid as a therapeutic target notwithstanding, the underlying causes of beta-amyloid aggregation in the human brain, however, remain to be elucidated. Multiple lines of evidence point towards an important role of infectious agents and/or inflammatory conditions in the etiology of AD. Various microorganisms have been detected in the cerebrospinal fluid and brains of AD-patients and have thus been hypothesized to be linked to the development of AD, including Porphyromonas gingivalis (PG) and Spirochaetes. Intriguingly, these microorganisms are also found in the oral cavity under normal physiological conditions, which is often affected by multiple pathologies like caries or tooth loss in AD patients. Oral cavity pathologies are mostly accompanied by a compositional shift in the community of oral microbiota, mainly affecting commensal microorganisms and referred to as ‘dysbiosis’. Oral dysbiosis seems to be at least partly mediated by key pathogens such as PG, and it is associated with a pro-inflammatory state that promotes the destruction of connective tissue in the mouth, possibly enabling the translocation of pathogenic microbiota from the oral cavity to the nervous system. It has therefore been hypothesized that dysbiosis of the oral microbiome may contribute to the development of AD. In this review, we discuss the infectious hypothesis of AD in the light of the oral microbiome and microbiome-host interactions, which may contribute to or even cause the development of AD. We discuss technical challenges relating to the detection of microorganisms in relevant body fluids and approaches for avoiding false-positives, and introduce the antibacterial protein lactoferrin as a potential link between the dysbiotic microbiome and the host inflammatory reaction.
Introduction
Dementia can be described as a mostly age-associated cognitive decline, with associated deficits in the areas of memory, language, problem solving and activities of daily life. The general cause of dementia is the loss or destruction of neurons as a result of different pathological processes (Gaugler et al., 2016).
Alzheimer´s disease (AD) is a progressive neurodegenerative disease and the most common form of dementia. It slowly impairs cognition and was first described more than 100 years ago by the German psychiatrist and neurologist Alois Alzheimer (Gaugler et al., 2016).
In the US more than 10% of the population aged 65 years and over, and about one third of the population aged 85 years and over, are diagnosed with AD (Gaugler et al., 2016). In Germany 1.2 million people are diagnosed with dementia of which 50-70% fulfil the clinical criteria of AD (DGPPN, DGN, AWMF, 2016). Regarding the demographic shift and increasing life expectancy in western countries these numbers will probably grow within the next years, which represents a major challenge for health care systems (Gaugler et al., 2016).
In the context of AD, characteristic changes in the brain can be observed at the macroscopic, microscopic and molecular levels. There is a pronounced brain atrophy and, as a result, a decrease in the total weight of the brain. At the histological level, two types of protein/peptide deposits are prominently observed: Intracellular fibrils from the hyperphosphorylated, microtubule-associated protein tau (neurofibrillary tangles) and extracellular plaques from the peptides amyloid-βeta-40 and -42 (Aβ) (Fan et al., 2019; Sengoku, 2020). In addition, mitochondrial dysfunction and pronounced neuroinflammation with activation of microglia and astrocytes can be observed (Wilkins and Swerdlow, 2016).
Although most clinical trials primarily targeting Aβ and tau have not been successful (Avgerinos et al., 2021., Liu and Wang, 2019; Lu et al., 2020), a recent study indicates clinical benefit in participants with early AD under treatment with an antibody binding soluble amyloid-beta protofibrils (Lecanemab) (van Dyck et al., 2022). Even though further clinical trials are needed to determine the long-term efficacy of Lecanemab, these results provide strong support for the so-called ‘amyloid hypothesis’. However, the underlying causative mechanisms of amyloid generation and inflammation in the brain remain to be elucidated.
In this review, we discuss the potential contribution of the oral microbiome and oral infectious agents to the etiology of AD, and their link to host inflammatory conditions.
Oral microbiota and the oral microbiome
One of several more recent hypotheses regarding the etiology of AD is a connection between AD and the oral microbiome. The oral microbiome describes the totality of microbial life in the human oral cavity. The mouth with lips, tongue, tonsils, palate, teeth, gums, supra- and subgingival space offers a variety of niches, representing a variety of ecological conditions for microorganisms. The oral microbiome is exposed to a broad set of environmental influences, including, for example, physical and chemical irritation from food intake, smoking, and dental hygiene. Next to the gastrointestinal microbiome, the oral microbiome is considered the most diverse in humans and consists of about 770 bacterial, fungal, archaeal and viral species. The oral microbiome exhibits strong inter-individual variation and also varies between different anatomical niches in the oral cavity (Fox et al., 2019; Sureda et al., 2020).
Under physiological conditions, the microbiome is thought to have a symbiotic character. Various environmental and immunological factors, however, can lead to a loss of microbial homeostasis, associated with an increase in disease-promoting, proinflammatory microorganisms and impaired immunological tolerance, which could result in tissue destruction with a systemic inflammatory response (Sudhakara et al., 2018; Bell et al., 2019; Fox et al., 2019; Sureda et al., 2020). Oral pathologies and, above all, periodontal disease (PD) as a polymicrobial, inflammatory condition involving pronounced tissue destruction could be a possible manifestation of oral dysbiosis (Bell et al., 2019; Fox et al., 2019).
Oral pathologies are linked to the development of Alzheimer´s disease (AD)
Numerous studies have pointed towards the possibility of a connection between AD and pathologies of the oral cavity, especially PD. This connection is likely bidirectional in nature. PD refers to the inflammatory-infectious destruction of the periodontium. It is accompanied by an increase in systemic inflammatory parameters (Paraskevas et al., 2008; Passoja et al., 2010). Through systemic inflammation, PD could contribute to the development of AD (Watts et al., 2008). This could for example be mediated by a worsening of neuroinflammation (Teixeira et al., 2017), or a disruption of the blood-brain barrier (Varatharaj and Galea, 2017).
Furthermore, multiple cross-sectional studies have shown an association between tooth loss (a typical result of severe PD) and cognitive impairment, silent infarctions and changes in white matter of the central nervous system (Grabe et al., 2009; Takata et al., 2009; Minn et al., 2013; Naorungroj et al., 2013; Park et al., 2013; Ranjan et al., 2019). Other cross-sectional studies have shown an association of the clinical diagnosis of PD with cognitive decline (Martande et al., 2014; Gil-Montoya et al., 2015; Sung et al., 2019). This correlation seems more pronounced in AD-type dementias than in other dementias (Tiisanoja et al., 2019).
In accordance with cross-sectional study results, longitudinal studies have also shown an association between early tooth loss and increased risk of cognitive decline, memory impairment and dementia. Conversely, the incidence of dementia was reduced after PD treatment (Stein et al., 2007; Kaye et al., 2010; Paganini-Hill et al., 2012; Yamamoto et al., 2012; Batty et al., 2013; Reyes Ortiz et al., 2013; Okamoto et al., 2015; Stewart et al., 2015; Yoo et al., 2019). Takeuchi et al. also showed an increased risk of AD due to tooth loss, but not for vascular dementia, a form a cognitive decline caused by arteriosclerosis of brain vessels (Takeuchi et al., 2017). Similar to early tooth-loss, PD diagnosis has also been associated in longitudinal studies with an increased risk of mild cognitive impairment (MCI), dementia and AD, as well as increased cognitive decline in AD-patients (Ide et al., 2016; Chen et al., 2017; Choi et al., 2019; Iwasaki et al., 2019, Lee et al., 2017a, Lee et al., 2017b). However, these results exhibit a greater degree of inconsistency (Wu et al., 2016; Tonsekar et al., 2017), probably due to widely varying methods for determining PD (Naorungroj et al., 2013).
Regardless of the clinical diagnosis of AD, some studies have linked PD in otherwise cognitively healthy, older subjects to AD-like neuropathological changes, including increased Aβ load in the brain (Kamer et al., 2015) and increased blood amyloid and inflammatory markers (Gil-Montoya et al., 2017; Leira et al., 2020). This suggests that oral inflammatory processes may precede the development of AD.
It is assumed that PD is best understood as a consequence or expression of oral dysbiosis - defined as ‘perturbation to the structure of complex commensal communities’ leading to diseases (Petersen and Round, 2014), rather than as an infection by specific pathogens. 16S rDNA sequencing has shown that the oral microbiome in PD is fundamentally different from the oral microbiome in healthy controls, and that progression of the disease also leads to changes in microbial composition (Zhang et al, 2020). In addition, an upregulation of bacterial genes involved in proteolysis, bacterial tissue invasion and subversion of the immune system could be observed (Yost et al., 2015). It has also been demonstrated that dysbiotic conditions are associated with the increased production of virulence factors by bacteria not associated with PD under normal conditions. For example, several species of Streptococcus, not classified as periodontal pathogens, participate in the transcription of virulence factors in the dysbiotic community (Yost et al., 2015). Finally, the severity of oral dysbiosis is linked to the severity of PD (Zhang et al., 2020).
Oral dysbiosis towards a pro-inflammatory environment with dominance of disease-promoting species seems to emerge from the synergism between individual key players – above all the gram-negative, anaerobic bacterium Porphyromonas gingivalis (PG) –with other bacteria with lower individual pathogenic potential (Zhang et al., 2020). This is consistent with the fact that PG was not able to trigger PD in sterile mouse models without a pre-existing microbiome, as it apparently needs the support of other, more opportunistic microorganisms to generate dysbiosis (Darveau, 2010). These findings are supported by a recent systematic review of studies regarding changes of the oral microbiome after periodontal interventions, including the mechanical removal of plaque, antiseptics, systemic administration of antibiotics, or combinations of these methods. The authors concluded that these interventions resulted in a complex shift of the whole oral ecosystem rather than a ‘simple’ eradication of pathogens (Zhang et al., 2021).
Infective agents involved in oral dysbiotic shift favoring AD
PG has been described as a ‘keystone pathogen’ of oral dysbiosis, meaning that it induces a shift of the symbiotic microbiota to a disease-promoting dysbiotic state, resulting in the clinical manifestation of PD (Darveau, 2010). In fact, however, the effect of PG seems to be dependent on the shift of the ecological system as a whole: The infection of germ-free mice with PG alone did not result in PD, underlining the dysbiotic nature of this disease (Darveau et al., 2012). This observation raises the question, if the colonization with PG could also be a consequence of a previous shift in the microbial community. In this scenario, an initial dysbiosis might result in optimal conditions for PG to infect the mouth. However, it was observed that infection of ‘specific-pathogen-free’ mice, which have a defined PG-free but otherwise normal oral microbiome, with PG resulted in a dysbiotic shift of the microbiome and later PD-associated alveolar bone loss (Darveau et al., 2012), consistent with the theory that PG can contribute to the development of PD.
In this sense, PG has also been described as a ‘pathobiont’. This term refers to a microorganism that typically exists in a synergistic, non-pathogenic state in its host, but which has the potential of becoming pathogenic under certain conditions. In the case of PG it has been postulated that a low-abundance colonization of the mouth with PG may not be pathogenic. The accumulation of bacterial plaque, however, for example because of poor oral hygiene, may lead to the initiation of innate immune systems defense mechanisms, resulting in a first state of inflammation. At a certain point, this inflammation ‘awakens’ PG in its pathogenic potential, which then starts to promote inflammation and a microbial shift, for example by infecting mucosal dendritic cells resulting in an uncontrolled inflammation mediated by the adaptive immune system (Meghil and Cutler, 2020). PG thus likely exerts its effects dependent on opportunistic microbes. Furthermore, the effect of PG also likely depends on the host immune response, with PG alone unable to induce PD-associated alveolar bone loss in mice deficient of specific CD4+-cells or several cytokines (Baker et al., 1999).
In addition to its connection to oral dysbiosis, PG is also directly associated with AD. In a retrospective analysis, 2355 participants over 60 years from the third National Health and Nutrition Examination Survey (NHANES-III) were screened for an association between cognitive performance tests and serum levels of PG-IgG-antibodies. Comparing individuals with the highest and lowest levels of PG-IgG, people with higher levels were more likely to have impaired delayed verbal recall and serial subtraction capabilities. This association of poor cognitive performance and PG-antibodies remained robust after adjusting for socioeconomic and vascular variables (Noble et al., 2009). However, in a case-cohort study from the same working-group with 219 subjects, higher serum levels of PG-IgG were not associated with incident AD. Nevertheless, elevated levels of antibodies against the periodontal, dysbiosis-associated bacteria Actinomyces naeslundii and Eubacterium nodatum were associated with an elevated risk for AD (Noble et al., 2014).
Later on, post mortem brain samples of AD-patients and neurologically normal individuals were immunohistochemically studied for the PG-protease gingipain, showing a significant correlation of the abundance of gingipain with AD diagnosis and the abundance of tau protein. This is especially interesting, as the same group also showed, that tau can be a target of gingipain proteolysis (Dominy et al., 2019). The proteolysis of tau is thought to generate toxic fragments, involved in AD pathology (Boyarko and Hook, 2021).
Additionally, Dominy et al. identified PG-DNA in AD brains and in the brains of gingipain-positive brain samples from patients without diagnosed dementia by using quantitative PCR. In a similar way, PG-DNA was also detected in the cerebrospinal fluid and saliva of ten non-deceased subjects with mild to moderate cognitive impairment, diagnosed with probable AD. They detected PG-DNA in seven of ten cerebrospinal fluid samples and ten of ten saliva samples (Dominy et al., 2019).
In experimental studies mice exposed intraperitoneally to the lipopolysaccharide (LPS) of PG developed learning and memory impairment, Aβ accumulation, and microglia-mediated neuroinflammation (Wu et al., 2017). In addition, oral administration of PG to mice triggered Aβ production, neurodegeneration and neuroinflammation (Ilievski et al., 2018). Vice versa, the administration of a small-molecule inhibitor of gingipain in mice orally infected with PG led to reduced amyloid production and neuroinflammation and was associated with increased survival of hippocampal neurons (Dominy et al., 2019).
The detection of PG-DNA and proteins in the central nervous system may be accounted for the presence of PG in the central nervous system. This however, raises the question, how the bacterium can be translocated to the brain? Bacterial outer-membrane vesicles are an alternative explanation for the presence of bacterial components in the central nervous systems. They can contain microbial genetic material, LPS and virulence factors. In the case of PG, outer-membrane vesicles have been shown to also contain gingipain (Castillo et al., 2022). A potential role of the protease gingipain or other virulence factors in the pathogenesis of AD is thus conceivable even in the absence of viable PG in the central nervous system (Nara et al., 2021). Nevertheless, false-positive detections are also a possible explanation for the presence of PG-DNA in the brain.
In addition to PG, other classes of bacteria that have the potential to generate bacterial amyloids and biofilms have been identified, especially comprising the phylum Spirochaetota and its member genus Treponema. Spirochaetes, including Treponema, are known to form biofilms through the synthesis of amyloids, enabling the formation of aggregated colonies in the central nervous system. This phenomenon is classically associated with neuro-lues and neuro-borreliosis by Treponema pallidum and Borrelia burgdorferi (Miklossy, 2016). What is more, Spirochaetes seem to be able to produce Aβ protein precursor (AβPP) and AβPP-like proteins as well (Miklossy, 1993). When formed in-vitro, spirochetal biofilms contain these main components of senile AD plaques. Vice versa, spirochetal DNA was found in senile plaques (Miklossy, 2016). The oral cavity is a rich source of different Treponema lineages, many of which are associated with the pathogenesis of PD (Zeng et al., 2021). Treponema DNA could be found post-mortem in the cortex of AD patients, as well as in the trigeminal ganglia, potentially implying a scenario of oral Treponema spp. being transported via cranial nerves (Riviere et al., 2002).
It is important to note that extracellular DNA is a structural component of bacterial biofilms (Whitchurch et al., 2002). Both spirochetal biofilms and senile plaques contain AD-associated proteins as well as spirochetal DNA. The potential of a direct connection between senile plaques and bacterial biofilms has therefore been proposed (Miklossy, 2016).
Oral dysbiotic signatures are associated with the development of cognitive decline and AD
There are several studies investigating a possible connection between the oral microbiome community structure and AD. Through a MEDLINE search (search terms: ‘oral microbiota’, ‘oral microbiome’ and ‘alzheimer’, ‘dementia’, ‘cognitive’, ‘cognition’), we identified 13 studies investigating the connections between AD and the oral microbiome (Cockburn et al., 2012; Liu et al., 2019; Bathini et al., 2020; Holmer et al., 2021; Wu et al., 2021; Yang et al., 2021; Chen et al., 2022a; Chen et al., 2022b; Chen et al., 2022c; Cirstea et al., 2022; Fu et al., 2022; Taati Moghadam et al., 2022; Tadjoedin et al., 2022). For Chen et al. 2022a and Cirstea et al., 2022, full-text manuscripts could not be obtained. For these studies, the following synopsis is based on information available in the abstracts. The details of all studies are summarized in Table 1.
Table 1 Studies investigating the oral microbiome of people with AD, dementia, or cognitive impairment.
The included studies were published between 2012 (Cockburn et al., 2012) and 2022 (Chen et al., 2022a). The number of participants ranged from ten (Cockburn et al., 2012) to 172 (Chen et al., 2022c) with a mean of 72 participants.
Twelve studies had a cross-sectional design with one examination where a group of patients (cases) with AD, dementia, or cognitive impairment is compared to a control group of healthy individuals. Five studies (Cockburn et al., 2012; Bathini et al., 2020; Holmer et al., 2021; Yang et al., 2021; Chen et al., 2022c) additionally included a third group of MCI patients, or people with subjective cognitive decline, or further differentiated into mild and moderate AD (Chen et al., 2022c). Chen et al. (b) had no healthy control group, but divided their AD patients into three groups regarding the patients’ nutritional habits (Chen et al., 2022b), based on the so-called ‘dietary inflammatory index’ (DII) (Phillips et al., 2019). One study employed a longitudinal design without a control group, but with a comparison of the oral microbiota before and after a 24-week oral health intervention (Chen et al., 2022a). Therefore, the studies of Chen et al., 2022a; Chen et al., 2022b) are excluded from the discussion regarding possible differences between patients and healthy controls. Nevertheless, they should be mentioned in the broader context of the oral microbiome in AD.
For the diagnosis of dementia and the exclusion of dementia/cognitive impairment in the healthy controls, eleven studies used the mini mental status examination (MMSE) as a clinical diagnostic in accordance with current guidelines (DGPPN, DGN, AWMF, 2016). Two studies additionally used cranial MRT (magnetic resonance tomography) or CT (computer tomography) (Chen et al., 2022c; Taati Moghadam et al., 2022).
The material used, to investigate the oral microbiome varied across the studies. Four studies used saliva (Liu et al., 2019; Bathini et al., 2020; Yang et al., 2021; Fu et al., 2022), seven used subgingival samples (Chen et al., 2022a; Chen et al., 2022b; Chen et al., 2022c), Cockburn et al., 2012; Holmer et al., 2021; Taati Moghadam et al., 2022; Tadjoedin et al., 2022), four used supragingival samples (Holmer et al., 2021; Wu et al., 2021; Chen et al., 2022b; Taati Moghadam et al., 2022), and three studies included additional fecal samples (Chen et al., 2022b; Chen et al., 2022c; Cirstea et al., 2022). Moghadam et al. also included samples from the buccal mucosa, the tongue and the teeth surface (Taati Moghadam et al., 2022).
For interrogating the structure of the oral microbiome, all included studies, with the exception of Taati Moghadam et al., 2022, relied on 16S rDNA sequencing. Briefly, 16S rDNA sequencing involves amplifying and sequencing the ubiquitous 16S ribosomal RNA gene (16S rDNA), followed by identification of the detected sequences in databases. 16S rDNA sequencing enables a characterization of the biological diversity and the individual abundances of oral bacteria (Suárez Moya, 2017). Except for Wu et al., the included studies employed the Illumina short-read sequencing platform, typically targeting the V3–V4 hypervariable regions of the bacterial 16S rRNA gene (Suárez Moya, 2017). Wu et al. carried out a full-length analysis (V1-9) of the bacterial 16S rRNA gene using the PacBio sequencing platform (Wu et al., 2021). Moghadam et al. performed a quantitative real-time PCR for periodontal pathogens (Taati Moghadam et al., 2022), limited to quantifying the abundances of pre-specified bacterial species.
Four studies found no difference in the alpha diversity between cases and controls (Cockburn et al., 2012; Bathini et al., 2020; Fu et al., 2022; Tadjoedin et al., 2022). Chen et al., 2022b also found no difference in alpha diversity between AD patients with different dietary inflammatory indices (DIIs) (Chen et al., 2022b). By contrast, four studies found a lower alpha diversity in cases compared to controls (Liu et al., 2019; Wu et al., 2021; Yang et al., 2021; Chen et al., 2022c), while two studies found a higher alpha diversity (Holmer et al., 2021, Cirstea et al., 2022). The results of the included studies with respect to alpha diversity were thus not consistent.
With respect to beta diversity, all studies identified differentially abundant taxonomic groups between case and control groups. It is important to note, however, that comparability of the studies was limited by varying sampling locations in the mouth (saliva, sub-/supragingival, teeth, tongue, buccal mucosa) and differences in control groups (cognitively healthy, people with subjective cognitive decline, mild cognitive impaired). Also, the statistical methods to define significant differences between groups varied, with three studies (Liu et al., 2019; Chen et al., 2022c; Fu et al., 2022) including linear discriminant analysis of effect size (LEfSe) (Segata et al., 2011) and only four studies (Cockburn et al., 2012; Yang et al., 2021; Chen et al., 2022c; Tadjoedin et al., 2022) explicitly mentioning the use of a multiple testing correction method, important for compositional analysis of the microbiome (Gloor and Reid, 2016).
The included studies’ results with respect to differentially abundant taxonomic groups are presented in detail in Table 1. It is important to note a general lack of consistency across studies. This may be due to the limited size or heterogeneity of the included study populations; some reported results may also be due to contamination (also see the next section on reducing the rate of false-positive detections in sequencing-based studies). In addition, species considered as oral pathogens were identified at both higher (e.g. Slackia exigua, Porphyromonas gingivalis, Capnocytophaga sp., Eubacterium infirmum, Prevotella buccae, Fusobacterium nucleatum, Prevotella intermedia, Treponema denticola, all associated with oral diseases (Spratt et al., 1999; Maestre et al., 2007; Hiranmayi et al., 2017; Mohanty et al., 2019)) and lower (Filifactor villosus, Filifactor alocis, Prevotella tannerae, Streptococcus mutans, Porphyromonas gingivalis (Hajishengallis and Lamont, 2012; Hajishengallis et al., 2012; Lemos et al., 2019; Mohanty et al., 2019; Jiang et al., 2021; Könönen et al., 2022)) abundances in cases compared to controls across studies. What is more, sometimes the same species (e.g. Porphyromonas gingivalis) was detected at both higher and lower abundances in different studies.
Having noted these limitations, we briefly summarize the included studies’ results in the following paragraphs.
At the phylum level, taxa found at higher abundance in cases include Firmicutes (Wu et al., 2021; Yang et al., 2021; Chen et al., 2022c), Actinobacteria (Yang et al., 2021), and Fusobacteria (Chen et al., 2022c). By contrast, some studies found a lower abundance of Fusobacteria (Wu et al., 2021), as well as of Patescibacteria, Synergistetes (Yang et al., 2021) and Proteobacteria (Chen et al., 2022c) in cases.
At the genus level, a higher abundance in cases was found for Prevotella (Cockburn et al., 2012), Moraxella (Liu et al., 2019), Leptotrichia (Liu et al., 2019; Chen et al., 2022c), Sphearochaeta (Liu et al., 2019), Lactobacillus, Actinomyces (Wu et al., 2021), Streptococcus, Veillonella (Wu et al., 2021; Chen et al., 2022c), Selenomonas (Chen et al., 2022c), Porphyromonas, Treponema (Tadjoedin et al., 2022), Kingella, Mogibacterium and Gemella (Liu et al., 2019). Lower abundances were found for Fusobacterium (Cockburn et al., 2012; Wu et al., 2021), Rothia (Liu et al., 2019), Actinomyces (Holmer et al., 2021), Porphyromonas (Wu et al., 2021; Yang et al., 2021), Cardiobacterium (Wu et al., 2021), Prevotella (Yang et al., 2021), Aggretibacter, Pseudomonas and Lautropia (Chen et al., 2022c).
Finally, at the species level, cases showed higher abundances of Leptotrichia wadei, Cardiobacterium valvarum (Bathini et al., 2020), Prevotella oulorum, Slackia exigua (Holmer et al., 2021), Porphyromonas gingivalis (Cirstea et al., 2022, Taati Moghadam et al., 2022; Tadjoedin et al., 2022), Capnocytophaga sp. oral clone DZ074, Eubacterium infirmum, Prevotella buccae, Selenomonas artemidis (Fu et al., 2022), Fusobacterium nucleatum, Prevotella intermedia (Taati Moghadam et al., 2022) and Treponema denticola (Tadjoedin et al., 2022). By contrast, lower abundances could be found for Filifactor villosus, Filifactor alocis, Porphyromonas gingivalis, Prevotella tannerae (Bathini et al., 2020), Rothia aeria, Corynebacterium durum (Holmer et al., 2021), Streptococcus mutans and Rothia dentocariosa (Fu et al., 2022).
In summary, no clear oral microbiome signature of AD could so far be identified. Results with respect to PG, characterized as a keystone pathogen of oral microbiome dysbiosis (see above), were also not consistent. Furthermore, an important limitation of the summarized studies is the potentially confounding role of reverse causality. For example, shifts in the oral microbiome structure of AD patients may be partly explained by changed patterns of personal oral hygiene due to the onset of dementia or pre-dementia (Naorungroj et al., 2013).
Nevertheless, the fact that all included studies found significant differences between cases and controls suggests a potentially important role of oral microbiome dysbiosis in the pathogenesis of AD. Pathogenicity of oral pathogens is not necessarily linked to high abundance (Meghil and Cutler, 2020), and microbial phenotypes, linked to e.g. virulence factors not detectable by 16S rDNA sequencing, may also play an important role.
Reducing the false-positive detection rate in sequencing-based studies
Both the existence of a ‘brain microbiome’ – that is, the microbial colonization of the brain under normal physiological conditions – as well as the colonization of the brains of neurodegenerative disease patients by specific pathogens such as PG have remained controversial (Link, 2021). Interrogating samples with low or no bacterial biomass with respect to the presence of specific bacterial species or bacterial community structure is well-known to be a challenging problem (also evident in the controversies around the existence of placental and blood microbiomes (Castillo et al., 2019; de Goffau et al., 2019; Blaser et al., 2021) potentially affected by multiple methodological biases that may lead to false-positive detections (Eisenhofer et al., 2019). This includes the so-called ‘contaminome’ – the contamination of DNA extraction and sequencing kits with bacterial DNA fragments (Salter et al., 2014; Glassing et al., 2016; Chrisman et al., 2022), as well as bioinformatic challenges, e.g. with respect to the reliable assignment of 16S sequencing data (Edgar, 2018) and the contamination of reference databases (Lu and Salzberg, 2018; Steinegger and Salzberg, 2020). Due to the additional amplification step, studies based on the 16S rDNA sequencing are generally more prone to false-positives than studies based on metagenomic shotgun sequencing. On the other hand, the presence of large quantities of host genetic material may reduce the sensitivity of metagenomic approaches. Recommendations (Eisenhofer et al., 2019) to reduce false-positive detection rates include (1) the use of negative controls, (2) characterization of the ‘contaminomes’ of the utilized reagents, (3) validation of potential detections using different DNA extraction and sequencing kit, (4) combination of different microbiome sequencing approaches, such as 16S rDNA sequencing and metagenomic sequencing and (5) the application of contamination detection algorithms (Liu et al., 2022).
In the case of 16S rDNA sequencing, full-length 16S rDNA sequencing approaches (Curry et al., 2022) may exhibit reduced false-positive rates. In the case of shotgun metagenomics, assessing the k-mer spectrum (Breitwieser et al., 2018) or the uniformity of horizontal reference genome coverage of the reads assigned to a taxon can be used to effectively filter out false-positive detections associated with nonspecific assignments, driven e.g. by eukaryotic repeat motifs, and reference database contamination.
Lactoferrin and its influence on oral health, PG and the central nervous system
In addition to the presence, absence and differential abundance of different microbes, host factors may also play an important role in the emergence of oral dysbiosis. Lactoferrin (LF) is a multifunctional human protein present on several mucosal surfaces and in several body fluids as milk and tears that may represent a possible link between the oral microbiome, PG and the central nervous system. It exhibits structural similarities to transferrin and is capable of binding iron (Fe3+), the iron-saturated form of LF being referred to as ‘holo-LF’ and the iron-free form referred to as ‘apo-LF’. LF fulfils a broad spectrum of different functions in the body (Wang et al., 2019). For example, it improves intestinal iron-absorption by binding Fe3+, followed by binding to a specific LF-receptor and internalization (Lönnerdal, 1994; Lönnerdal et al., 2011). It also functions as an antioxidant (Faridvand et al., 2017), reduces bacterial growth (Lynge Pedersen and Belstrøm, 2019; Lu et al., 2021), inhibits the invasion of viruses (Miotto et al., 2021) and modulates inflammatory processes (Puddu et al., 2011).
Salivary LF plays a key role in maintaining the health and general homeostasis of the mouth. It is produced in the salivary glands and its production is upregulated during states of infection and inflammation (Glimvall et al., 2012). LF is capable of inhibiting typical oral pathogens including bacteria (e.g. Streptococcus mutans, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans), viruses (e.g. Herpes simplex) and fungi (e.g. Candida albicans) (Lynge Pedersen and Belstrøm, 2019).
Especially with respect to PD, LF fulfils key functions inhibiting disease initiation and progression. For example, biofilms on the tooth surfaces support the growth of proinflammatory bacteria, leading to lesions of the mucosal connective tissue and gingival bleeding. As a consequence, the availability of hemoglobin and iron in the oral fluids is increased, contributing to the growth for key periodontal pathogens, such as PG, and further reinforcing the inflammatory process. By binding free iron, LF inhibits the growth of bacterial pathogens, leading to the downregulation of the inflammatory loop and reduction of oral pathology (Lynge Pedersen and Belstrøm, 2019).
Interestingly, LF also seems to play a role in maintaining iron homeostasis in the central nervous system. AD patients show increased concentrations of iron in their brain (Smith et al., 2010; Yang et al., 2022). Disturbed iron metabolism may result in neuronal dysfunction and neuronal death, as iron and other metals are associated with potential neural toxicity and trigger increased lipid-peroxidation (Liu et al., 2018).
Similar to the oral upregulation of LF under inflammatory conditions, LF can also be upregulated in the central nervous system, mediated by LF secretion by microglia. Probably in response to increased free iron concentrations in the brains of AD patients, the LF concentration in the brains of these patients is also elevated (Liu et al., 2018). A transcriptomic analysis of neuropathological samples found that upregulated transcription of LF best differentiated between AD patients and controls and showed the highest correlation to Aβ-pathology. Also, an involvement of LF in the processing of APP could be demonstrated. Together, this suggests, that increased transcription of LF in the central nervous system is a core feature of AD pathology (Tsatsanis et al., 2021).
Lactoferrin’s antibacterial activity may be of particular relevance in the context of its activity against PG. Several studies were able to identify mechanisms by which LF inhibits PG: It (1) is able to bind PG and other oral pathogens (Kalfas et al., 1991), (2) can agglutinate PG and inhibits its auto aggregation relevant for its biofilm formation (Soukka et al., 1993), (3) inhibits the growth of PG by binding and withdrawing iron as a growth factor (Aguilera et al., 1998), (4) removes the hemoglobin receptor on the cell surface of PG, disrupting the iron metabolism (Shi et al., 2000), (5) inhibits the adhesion of PG and other oral pathogens on surfaces (Arslan et al., 2009; Wakabayashi et al., 2009) and (6) inhibits the proteinases of PG, functioning as key pathogenic factors in PD (Dashper et al., 2012).
On the other hand, PG and other oral pathogens are able to bind and degrade LF (Alugupalli and Kalfas, 1996; de Lillo et al., 1996). In addition, PG can induce the expression of micro-RNA-584 in human gingival epithelial cells, which can inhibit the expression of LF-receptors and reduces the anti-inflammatory effect of LF (Ouhara et al., 2014). The existence of these direct anti-LF mechanisms is consistent with the theory of LF as a central protective factor against PG. Interestingly, it has been shown, that AD-patients have reduced salivary concentrations of LF (Carro et al., 2017), which might be a consequence of the degradation of LF by PG or other dysbiotic mechanisms, resulting in a vicious cycle of insufficient defense and an increasingly inflammatory environment (Olsen and Singhrao, 2020).
Regarding the occurrence of PG and gingipain in the central nervous system of AD patients (Dominy et al., 2019), it was recently hypothesized that the increased availability of free iron in AD brains (Smith et al., 2010; Yang et al., 2022) may attract the migration of PG, as PG requires iron for its growth (Olsen, 2021). In this scenario, increased concentrations of LF in the AD brain could be interpreted as a protective mechanism against free iron and, potentially, PG migration.
Salivary lactoferrin as a non-invasive diagnostic tool for Alzheimer`s disease
The discovery of reduced concentrations of LF in the saliva of AD patients prompted several studies investigating the potential use of salivary LF in the diagnosis of AD. Compared to established diagnostic liquor parameters and imaging methods (DGPPN, DGN, AWMF, 2016), which are highly invasive and/or cost-intensive, the collection of saliva for diagnostic purposes can be implemented in a non-invasive and cost-effective manner.
Reduced levels of LF were first observed in the saliva of patients with oral dryness (xerostomia) (Mizuhashi et al., 2015). Xerostomia is a typical feature of the aging population, associated with a poorer oral health status and malnutrition. The condition can be seen as a sign of an altered function of the salivary gland (Xu et al., 2019).
Reduced salivary LF was found to better discriminate between cases and controls than tau and beta-amyloid-42 in the liquor in patients with AD and mild cognitive impairment (Carro et al., 2017). Reduced levels of salivary LF were also found to correlate with PET-measured amyloid load and to enable a differentiation between AD and frontotemporal dementia with a sensitivity of 87% and a specifity of 91% (González-Sánchez et al., 2020). In addition, Reseco et al. reported an association between reduced levels of LF and higher PET-measured amyloid load in the brain of even cognitively healthy, elderly people (Reseco et al., 2021).
These promising results notwithstanding, however, replication of the diagnostic utility of LF in additional studies and by independent research groups is required. A first study trying to reproduce the diagnostic use of salivary LF failed to find a correlation between salivary LF, clinical status and liquor parameters (Gleerup et al., 2021).
Therapeutic applications of lactoferrin
Several clinical studies have investigated whether the described antimicrobial and oral homeostasis-promoting properties of LF enable its use – typically in the form of bovine LF, which is found in cow’s milk and which exhibits a high degree of similarity to human LF – as a therapeutic agent against oral pathologies and oral microbiome dysbiosis (Rosa et al., 2021).
At least four studies (Daly et al., 2019, Ishikado et al., 2010; Nakano et al., 2016; Nakano et al., 2019) investigated the influence of LF in tablets, or toothpaste on clinical signs of PD, showing a positive impact on several clinical indices, inflammatory conditions and oral malodor. Six studies (Kondo et al., 2008; Shimizu et al., 2011; Shin et al., 2011; Adams et al., 2017; Morita et al., 2017; Nakano et al., 2017) also included microbiological parameters. In these papers, LF additionally to again positively influencing clinical parameters, lowered the number of PG, Prevotella intermedia and Fusobacterium nucleatum and promoted a presumed beneficial shift of the oral microbiome. The details of these studies are presented in Tables 2, 3.
Table 2 Studies on the therapeutic effects of LF on clinical signs of PD.
Table 3 Studies on the therapeutic effects of LF on microbiological parameters.
Some studies in model organisms also suggest that LF may have therapeutic utility in the field of neurodegenerative diseases. In mouse models of AD, nasal and oral application of LF led to reduced cognitive decline, lower concentration of Aβ and changes in protein expression of the brain, suggesting reduced inflammatory conditions and oxidative stress (Guo et al., 2017; Abdelhamid et al., 2020). In a nematode-model LF showed a reduction in paralysis as a result of the toxicity of Aβ, extended lifespan and upregulated genes involved in immune response, antioxidative defense, synaptic function and ubiquitin-mediated proteolysis (Martorell et al., 2017). However, further studies are required to better characterize the effect of LF in model organisms. The details of the studies are summarized in Table 4.
Table 4 Animal-studies on the therapeutic effects of LF on neurodegenerative diseases.
Finally, one clinical trial tried to investigate the therapeutic effect of LF in AD patients. Mohamed et al. designed a randomized, controlled trials with 50 patients (28 men, 22 women) with a clinical diagnosis of AD and a concordant MRT brain scan. They received 250mg of bovine LF per day or only the standard therapy. After three months, cases showed better results in the MMSE and AD assessment scale-cognitive subscale 11-item (ADAS-COG-11), higher concentrations of ACh and 5-HT, lower serum levels of markers of oxidative stress and inflammation, Aβ-42 and p-tau, a higher level of glutathione and changes in gene expression of peripheral blood lymphocytes (Mohamed et al., 2019).
Conclusion
In this review we summarized and discussed the evidence for a connection between the oral microbiota and the pathogenesis of AD. AD is characterized by cognitive decline and the aggregation of amyloid and tau. Due to a demographic shift associated with ageing populations in developed and developing countries, AD represents one of the most pressing health issues of the world.
The ‘amyloid hypothesis’ of AD is supported by a recent clinical trial demonstrating efficacy of an antibody against soluble amyloid-beta (van Dyck et al., 2022). The underlying causes of amyloid agglomeration and inflammation in the brain, however, remain to be elucidated.
Various lines of evidence support the potential relevance of oral microbiota in this context. These include (i) evidence for increased rates of oral pathologies, in which the oral microbiota play an important role, in AD patients; (ii) evidence for an association between AD and specific oral pathogens, in particular PG; (iii) evidence for oral microbiome community shifts in AD patients. It is important to note, however, the potentially confounding role of reverse causality, such as changed patterns of personal oral hygiene due to the onset of dementia or pre-dementia, and the limitations of cross-sectional study designs and 16S rDNA sequencing approaches.
On a functional level, a link between the oral microbiota and AD could be mediated by (i) the presence of viable oral-associated bacteria in the brain; or (ii) the translocation, possibly mediated by outer-membrane vesicles, of inflammation-inducing or beta-amyloid-aggregation-inducing bacterial material, such as gingipain or LPS (Nie et al., 2019), to the brain. Both types of functional mechanisms are similar in that (i) they are compatible with the reported increased detection of microbial DNA and proteins, including DNA and proteins of the oral dybiosis-associated keystone pathogen P. gingivalis, in the brains of AD patients; and in that (ii) they both involve an important role for oral dysbiosis, which is associated with injuries of mucosal connective tissues, likely increasing the probability of translocation of both bacterial materials and intact bacteria from the mouth. Furthermore, the protein Lactoferrin, which occurs orally as well as in the brain, and which exhibits direct antimicrobial activity and influences iron homeostasis, may play an important link between the oral microbiota and inflammatory conditions of the host. This hypothetical connection is illustrated in Figure 1. It is important to note that all of these discussed mechanisms are fully compatible with the ‘amyloid hypothesis’.
Figure 1 A hypothetical connection of the oral microbiome and AD might be a multi-step process with LF as a possible component in different stages and anatomical locations.
Oral dysbiosis and the occurrence of oral pathologies are increasingly understood as polymicrobial conditions, which involve a complex interplay between key pathogens such as PG and other, individually less pathogenic, bacteria. While studies of the oral microbiome structure and of the occurrence of PD in AD patients strongly support the hypothesis that AD is associated with both shifts in oral microbiome structure and oral pathologies, no clear picture of an ‘oral microbiome signature’ of AD has emerged yet.
It is important to note that, as it stands, the potential connections discussed in this review between AD and the oral microbiome and PG, as well as between AD and LF, are still hypothetical in nature. As we have shown, clinical studies are inconsistent with respect to specific microbiome features reported to be associated with AD; apart from the finding that the oral microbiomes of AD patients seem to differ from the oral microbiomes of controls, no clear microbiome signature associated with AD has been identified so far. Important limitations of most studies include a cross-sectional design and reliance on 16S rDNA sequencing, which is prone to false-positives; reported results have an observational character at best and should be interpreted with caution.
With these limitations in mind, we recommend that future studies aiming to elucidate the association between AD and the oral microbiota should include longitudinal study designs and employ multiple and complementary approaches to the characterization of oral microbiomes, including shotgun metagenomics. In addition to providing more accurate and robust estimates of community composition, metagenomics approaches can also yield insights into the functional capabilities of microbial communities, which may also play a role in the development of AD. We also recommend that future studies cover different niches of the oral cavity as well as the cerebral fluid, employing consistent methodologies for the detection and quantification of microbial signatures. Key questions include whether the pathogenesis of AD involves the presence of intact oral bacteria in the brain, whether it is possible to identify AD-promoting oral microbiome signatures and, indeed, whether therapeutic interventions targeting the oral microbiome may influence AD risk or prognosis.
Author contributions
CW, AD, and PF, text. CW, figures. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Abdelhamid, M., Jung, C.-G., Zhou, C., Abdullah, M., Nakano, M., Wakabayashi, H., et al. (2020). Dietary lactoferrin supplementation prevents memory impairment and reduces amyloid-β generation in J20 mice. J. Alzheimer’s Disease: JAD 74 (1), 245–259. doi: 10.3233/JAD-191181
Adams, S. E., Arnold, D., Murphy, B., Carroll, P., Green, A. K., Smith, A. M., et al. (2017). A randomised clinical study to determine the effect of a toothpaste containing enzymes and proteins on plaque oral microbiome ecology. Sci. Rep. 7, 43344. doi: 10.1038/srep43344
Aguilera, O., Andrés, M. T., Heath, J., Fierro, J. F., Douglas, C. W. (1998). Evaluation of the antimicrobial effect of lactoferrin on porphyromonas gingivalis, prevotella intermedia and prevotella nigrescens. FEMS Immunol. Med. Microbiol. 21 (1), 29–36. doi: 10.1111/j.1574-695X.1998.tb01146.x
Alugupalli, K. R., Kalfas, S. (1996). Degradation of lactoferrin by periodontitis-associated bacteria. FEMS Microbiol. Lett. 145 (2), 209–214. doi: 10.1111/j.1574-6968.1996.tb08579.x
Arslan, S. Y., Leung, K. P., Wu, C. D. (2009). The effect of lactoferrin on oral bacterial attachment. Oral. Microbiol. Immunol. 24 (5), 411–416. doi: 10.1111/j.1399-302X.2009.00537.x
Avgerinos, K. I., Ferrucci, L., Kapogiannis, D. (2021). Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in alzheimer’s disease. Ageing Res. Rev. 68, 101339. doi: 10.1016/j.arr.2021.101339
Baker, P. J., Dixon, M., Evans, R. T., Dufour, L., Johnson, E., Roopenian, D. C. (1999). CD4(+) T cells and the proinflammatory cytokines gamma interferon and interleukin-6 contribute to alveolar bone loss in mice. Infection Immun. 67 (6), 2804–2809. doi: 10.1128/IAI.67.6.2804-2809.1999
Bathini, P., Foucras, S., Dupanloup, I., Imeri, H., Perna, A., Berruex, J. L., et al. (2020). Classifying dementia progression using microbial profiling of saliva. Alzheimer’s Dementia: Diagn. Assess. Dis. Monitoring 12 (1), e12000.
Batty, G. D., Li, Q., Huxley, R., Zoungas, S., Taylor, B. A., Neal, B., et al. (2013). Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the action in diabetes and vascular disease: preterax and diamicron modified-release controlled evaluation (ADVANCE) trial. Eur Psychiatry 28 (1), 49–52. doi: 10.1016/j.eurpsy.2011.07.005
Bell, J. S., Spencer, J. I., Yates, R. L., Yee, S. A., Jacobs, B. M., DeLuca, G. C. (2019). Invited review: from nose to gut - the role of the microbiome in neurological disease. Neuropathol. Appl. Neurobiol. 45 (3), 195–215. doi: 10.1111/nan.12520
Blaser, M. J., Devkota, S., McCoy, K. D., Relman, D. A., Yassour, M., Young, V. B. (2021). Lessons learned from the prenatal microbiome controversy. Microbiome 9 (1), 8. doi: 10.1186/s40168-020-00946-2
Boyarko, B., Hook, V. (2021). Human tau isoforms and proteolysis for production of toxic tau fragments in neurodegeneration. Front. Neurosci. 15, 702788. doi: 10.3389/fnins.2021.702788
Breitwieser, F. P., Baker, D. N., Salzberg, S. L. (2018). KrakenUniq: confident and fast metagenomics classification using unique k-mer counts. Genome Biol. 19 (1), 198. doi: 10.1186/s13059-018-1568-0
Carro, E., Bartolomé, F., Bermejo-Pareja, F., Villarejo-Galende, A., Molina, J. A., Ortiz, P., et al. (2017). Early diagnosis of mild cognitive impairment and alzheimer’s disease based on salivary lactoferrin. Alzheimer’s Dementia: Diagn. Assess. Dis. Monit 8, 131–138. doi: 10.1016/j.dadm.2017.04.002
Castillo, D. M., Castillo, Y., Delgadillo, N. A., Neuta, Y., Lafaurie, G. I., Romero-Sánchez, C., et al. (2022). Purification of RgpA from external outer membrane vesicles of porphyromonas gingivalis. Anaerobe 77, 102647. doi: 10.1016/j.anaerobe.2022.102647
Castillo, D. J., Rifkin, R. F., Cowan, D. A., Potgieter, M. (2019). The healthy human blood microbiome: fact or fiction? Front. Cell. Infection Microbiol. 9, 148. doi: 10.3389/fcimb.2019.00148
Chen, L., Cao, H., Wu, X., Xu, X., Ji, X., Wang, B., et al. (2022a). Effects of oral health intervention strategies on cognition and microbiota alterations in patients with mild alzheimer’s disease: a randomized controlled trial. Geriatric Nurs. (New York N.Y.) 48, 103–110. doi: 10.1016/j.gerinurse.2022.09.005
Chen, L., Wang, B., Liu, J., Wu, X., Xu, X., Cao, H., et al. (2022b). Different oral and gut microbial profiles in those with alzheimer’s disease consuming anti-inflammatory diets. Front. Nutr. 9, 974694. doi: 10.3389/fnut.2022.974694
Chen, C. K., Wu, Y. T., Chang, Y. C. (2017). Association between chronic periodontitis and the risk of alzheimer’s disease: a retrospective, population-based, matched-cohort study. Alzheimer’s Res. Ther 9 (1), 56. doi: 10.1186/s13195-017-0282-6
Chen, L., Xu, X., Wu, X., Cao, H., Li, X., Hou, Z., et al. (2022c). A comparison of the composition and functions of the oral and gut microbiotas in alzheimer’s patients. Front. Cell. Infection Microbiol. 12, 942460. doi: 10.3389/fcimb.2022.942460
Choi, S., Kim, K., Chang, J., Kim, S. M., Kim, S. J., Cho, H.-J., et al. (2019). Association of chronic periodontitis on alzheimer’s disease or vascular dementia. J. Am. Geriatrics Soc. 67 (6), 1234–1239. doi: 10.1111/jgs.15828
Chrisman, B., He, C., Jung, J.-Y., Stockham, N., Paskov, K., Washington, P., et al. (2022). The human “contaminome”: bacterial, viral, and computational contamination in whole genome sequences from 1000 families. Sci. Rep. 12 (1), 9863. doi: 10.1038/s41598-022-13269-z
Cirstea, M. S., Kliger, D., MacLellan, A. D., Yu, A. C., Langlois, J., Fan, M., et al. (2022). The oral and fecal microbiota in a Canadian cohort of alzheimer’s disease. J. Alzheimer’s Disease: JAD 87 (1), 247–258. doi: 10.3233/JAD-215520
Cockburn, A. F., Dehlin, J. M., Ngan, T., Crout, R., Boskovic, G., Denvir, J., et al. (2012). High throughput DNA sequencing to detect differences in the subgingival plaque microbiome in elderly subjects with and without dementia. Invest. Genet. 3 (1), 19. doi: 10.1186/2041-2223-3-19
Curry, K. D., Wang, Q., Nute, M. G., Tyshaieva, A., Reeves, E., Soriano, S., et al. (2022). Emu: species-level microbial community profiling of full-length 16S rRNA Oxford nanopore sequencing data. Nat. Methods 19 (7), 845–853. doi: 10.1038/s41592-022-01520-4
Daly, S., Seong, J., Newcombe, R., Davies, M., Nicholson, J., Edwards, M., et al. (2019). A randomised clinical trial to determine the effect of a toothpaste containing enzymes and proteins on gum health over 3 months. J. Dentistry 80 Suppl 1, S26–S32. doi: 10.1016/j.jdent.2018.12.002
Darveau, R. P. (2010). Periodontitis: a polymicrobial disruption of host homeostasis. Nat. Rev. Microbiol. 8 (7), 481–490. doi: 10.1038/nrmicro2337
Darveau, R. P., Hajishengallis, G., Curtis, M. A. (2012). Porphyromonas gingivalis as a potential community activist for disease. J. Dental Res 91 (9), 816–20. doi: 10.1177/0022034512453589
Dashper, S. G., Pan, Y., Veith, P. D., Chen, Y.-Y., Toh, E. C. Y., Liu, S. W., et al. (2012). Lactoferrin inhibits porphyromonas gingivalis proteinases and has sustained biofilm inhibitory activity. Antimicrobial. Agents Chemother. 56 (3), 1548–1556. doi: 10.1128/AAC.05100-11
de Goffau, M. C., Lager, S., Sovio, U., Gaccioli, F., Cook, E., Peacock, S. J., et al. (2019). Human placenta has no microbiome but can contain potential pathogens. Nature 572 (7769), 329–334. doi: 10.1038/s41586-019-1451-5
de Lillo, A., Teanpaisan, R., Fierro, J. F., Douglas, C. W. (1996). Binding and degradation of lactoferrin by porphyromonas gingivalis, prevotella intermedia and prevotella nigrescens. FEMS Immunol. Med. Microbiol. 14 (2–3), 135–143. doi: 10.1111/j.1574-695X.1996.tb00280.x
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Neurologie (DGN) (2016). S3-leitlinie "Demenzen". AWMF, register number 038-013.
Dominy, S. S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., et al. (2019). Porphyromonas gingivalis in alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 5 (1), eaau3333. doi: 10.1126/sciadv.aau3333
Edgar, R. (2018). Taxonomy annotation and guide tree errors in 16S rRNA databases. PeerJ 6, e5030. doi: 10.7717/peerj.5030
Eisenhofer, R., Minich, J. J., Marotz, C., Cooper, A., Knight, R., Weyrich, L. S. (2019). Contamination in low microbial biomass microbiome studies: issues and recommendations. Trends Microbiol. 27 (2), 105–117. doi: 10.1016/j.tim.2018.11.003
Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., et al. (2019). New insights into the pathogenesis of alzheimer’s disease. Front. Neurol. 10, 1312. doi: 10.3389/fneur.2019.01312
Faridvand, Y., Nozari, S., Asoudeh-Fard, A., Karimi, M.-A., Pezeshkian, M., Safaie, N., et al. (2017). Bovine lactoferrin ameliorates antioxidant esterase activity and 8-isoprostane levels in high-cholesterol-diet fed rats. Int. J. Vitamin Nutr. Res. Internationale Z. Fur Vitamin- Und Ernahrungsforschung J. Int. Vitaminologie Nutr. 87 (3–4), 201–206. doi: 10.1024/0300-9831/a000516
Fox, M., Knorr, D. A., Haptonstall, K. M. (2019). Alzheimer’s disease and symbiotic microbiota: an evolutionary medicine perspective. Ann. New York Acad. Sci. 1449 (1), 3–24. doi: 10.1111/nyas.14129
Fu, K.-L., Chiu, M.-J., Wara-Aswapati, N., Yang, C.-N., Chang, L.-C., Guo, Y. L., et al. (2022). Oral microbiome and serological analyses on association of alzheimer’s disease and periodontitis. Oral. Dis 00, 1–11. doi: 10.1111/odi.14348
Gaugler, J., James, B., Johnson, T., Scholz, K., Weuve, J. (2016). 2016 alzheimer’s disease facts and figures. Alzheimer’s Dementia 12 (4), 459–509. doi: 10.1016/j.jalz.2016.03.001
Gil-Montoya, J. A., Barrios, R., Santana, S., Sanchez-Lara, I., Pardo, C. C., Fornieles-Rubio, F., et al. (2017). Association between periodontitis and amyloid β peptide in elderly people with and without cognitive impairment. J. Periodontol. 88 (10), 1051–1058. doi: 10.1902/jop.2017.170071
Gil-Montoya, J. A., Sanchez-Lara, I., Carnero-Pardo, C., Fornieles, F., Montes, J., Vilchez, R., et al. (2015). Is periodontitis a risk factor for cognitive impairment and dementia? a case-control study. J. Periodontol. 86 (2), 244–53. doi: 10.1902/jop.2014.140340
Glassing, A., Dowd, S. E., Galandiuk, S., Davis, B., Chiodini, R. J. (2016). Inherent bacterial DNA contamination of extraction and sequencing reagents may affect interpretation of microbiota in low bacterial biomass samples. Gut Pathog. 8, 24. doi: 10.1186/s13099-016-0103-7
Gleerup, H. S., Jensen, C. S., Høgh, P., Hasselbalch, S. G., Simonsen, A. H. (2021). Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for alzheimer’s disease in a mixed memory clinic population. EBioMedicine 67, 103361. doi: 10.1016/j.ebiom.2021.103361
Glimvall, P., Wickström, C., Jansson, H. (2012). Elevated levels of salivary lactoferrin, a marker for chronic periodontitis? J. Periodontal. Res. 47 (5), 655–660. doi: 10.1111/j.1600-0765.2012.01479.x
Gloor, G. B., Reid, G. (2016). Compositional analysis: a valid approach to analyze microbiome high-throughput sequencing data. Can. J. Microbiol. 62 (8), 692–703. doi: 10.1139/cjm-2015-0821
González-Sánchez, M., Bartolome, F., Antequera, D., Puertas-Martín, V., González, P., Gómez-Grande, A., et al. (2020). Decreased salivary lactoferrin levels are specific to alzheimer’s disease. J. Cleaner Production 57, 102834. doi: 10.1016/j.ebiom.2020.102834
Grabe, H. J., Schwahn, C., Volzke, H., Spitzer, C., Freyberger, H. J., John, U., et al. (2009). Tooth loss and cognitive impairment. J. Clin. Periodontol. 36 (7), 550–557. doi: 10.1111/j.1600-051X.2009.01426.x
Guo, C., Yang, Z.-H., Zhang, S., Chai, R., Xue, H., Zhang, Y.-H., et al. (2017). Intranasal lactoferrin enhances α-Secretase-Dependent amyloid precursor protein processing via the ERK1/2-CREB and HIF-1α pathways in an alzheimer’s disease mouse model. Neuropsychopharmacology 42 (13), 2504–2515. doi: 10.1038/npp.2017.8
Hajishengallis, G., Darveau, R. P., Curtis, M. A. (2012). The keystone-pathogen hypothesis. Nat. Rev. Microbiol. 10 (10), 717–725. doi: 10.1038/nrmicro2873
Hajishengallis, G., Lamont, R. J. (2012). Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol. Oral. Microbiol 27 (6), 409–19. doi: 10.1111/j.2041-1014.2012.00663.x
Hiranmayi, K. V., Sirisha, K., Ramoji Rao, M. V., Sudhakar, P. (2017). Novel pathogens in periodontal microbiology. J. Pharm. Bioallied Sci. 9 (3), 155–163. doi: 10.4103/jpbs.JPBS_288_16
Holmer, J., Aho, V., Eriksdotter, M., Paulin, L., Pietiäinen, M., Auvinen, P., et al. (2021). Subgingival microbiota in a population with and without cognitive dysfunction. J. Oral. Microbiol. 13 (1), 1854552. doi: 10.1080/20002297.2020.1854552
Ide, M., Harris, M., Stevens, A., Sussams, R., Hopkins, V., Culliford, D., et al. (2016). Periodontitis and cognitive decline in alzheimer’s disease. PloS One 11 (3), e0151081. doi: 10.1371/journal.pone.0151081
Ilievski, V., Zuchowska, P. K., Green, S. J., Toth, P. T., Ragozzino, M. E., Le, K., et al. (2018). Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PloS One 13 (10), e0204941. doi: 10.1371/journal.pone.0204941
Ishikado, A., Uesaki, S., Suido, H., Nomura, Y., Sumikawa, K., Maeda, M., et al. (2010). Human trial of liposomal lactoferrin supplementation for periodontal disease. Biol. Pharm. Bull. 33 (10), 1758–1762. doi: 10.1248/bpb.33.1758
Iwasaki, M., Kimura, Y., Ogawa, H., Yamaga, T., Ansai, T., Wada, T., et al. (2019). Periodontitis, periodontal inflammation, and mild cognitive impairment: a 5-year cohort study. J. Periodontal. Res 54 (3), 233–240. doi: 10.1111/jre.12623
Jiang, Q., Yu, Y., Xu, R., Zhang, Z., Liang, C., Sun, H., et al. (2021). The temporal shift of peri-implant microbiota during the biofilm formation and maturation in a canine model. Microbial. Pathogenesis 158, 105100. doi: 10.1016/j.micpath.2021.105100
Kalfas, S., Andersson, M., Edwardsson, S., Forsgren, A., Naidu, A. S. (1991). Human lactoferrin binding to porphyromonas gingivalis, prevotella intermedia and prevotella melaninogenica. Oral. Microbiol. Immunol. 6 (6), 350–355. doi: 10.1111/j.1399-302X.1991.tb00506.x
Kamer, A. R., Pirraglia, E., Tsui, W., Rusinek, H., Vallabhajosula, S., Mosconi, L., et al. (2015). Periodontal disease associates with higher brain amyloid load in normal elderly. Neurobiol. Aging 36 (2), 627–33. doi: 10.1016/j.neurobiolaging.2014.10.038
Kaye, E. K., Valencia, A., Baba, N., Spiro, A., 3rd, Dietrich, T., Garcia, R. I. (2010). Tooth loss and periodontal disease predict poor cognitive function in older men. J. Am. Geriatrics Soc. 58 (4), 713–718. doi: 10.1111/j.1532-5415.2010.02788.x
Kondo, I., Kobayashi, T., Wakabayashi, H., Yamauchi, K., Iwatsuki, K., Yoshie., H. (2008). Effects of oral administration of bovine lactoferrin on periodontitis patients. Japanese J. Conservative Dentistry 51, 281–291. doi: 10.11471/shikahozon.51.281
Könönen, E., Fteita, D., Gursoy, U. K., Gursoy, M. (2022). Prevotella species as oral residents and infectious agents with potential impact on systemic conditions. J. Oral. Microbiol. 14 (1), 2079814. doi: 10.1080/20002297.2022.2079814
Lee, Y. L., Hu, H. Y., Huang, L. Y., Chou, P., Chu, D. (2017a). Periodontal disease associated with higher risk of dementia: population-based cohort study in Taiwan. J. Am. Geriatrics Society 65 (9), 1975–1980. doi: 10.1111/jgs.14944
Lee, Y. T., Lee, H. C., Hu, C. J., Huang, L. K., Chao, S. P., Lin, C. P., et al. (2017b). Periodontitis as a modifiable risk factor for dementia: a nationwide population-based cohort study. J. Am. Geriatrics Soc 65 (2), 301–305. doi: 10.1111/jgs.14449
Leira, Y., Carballo, A., Orlandi, M., Aldrey, J. M., Pias-Peleteiro, J. M., Moreno, F., et al. (2020). Periodontitis and systemic markers of neurodegeneration: a case-control study. J. Clin. Periodontol. 47 (5), 561–571, doi: 10.1111/jcpe.13267
Lemos, J. A., Palmer, S. R., Zeng, L., Wen, Z. T., Kajfasz, J. K., Freires, I. A., et al. (2019). The biology of streptococcus mutans. Microbiol. Spectr. 7 (1), 10. doi: 10.1128/microbiolspec.GPP3-0051-2018
Link, C. D. (2021). Is there a brain microbiome? Neurosci. Insights 16, 26331055211018708. doi: 10.1177/26331055211018709
Liu, Y., Elworth, R. A. L., Jochum, M. D., Aagaard, K. M., Treangen, T. J. (2022). De novo identification of microbial contaminants in low microbial biomass microbiomes with squeegee. Nat. Commun. 13 (1), 6799. doi: 10.1038/s41467-022-34409-z
Liu, J.-L., Fan, Y.-G., Yang, Z.-S., Wang, Z.-Y., Guo, C. (2018). Iron and alzheimer’s disease: from pathogenesis to therapeutic implications. Front. Neurosci. 12, 632. doi: 10.3389/fnins.2018.00632
Liu, X.-X., Jiao, B., Liao, X.-X., Guo, L.-N., Yuan, Z.-H., Wang, X., et al. (2019). Analysis of salivary microbiome in patients with alzheimer’s disease. J. Alzheimer’s Disease: JAD 72 (2), 633–640. doi: 10.3233/JAD-190587
Liu, J., Wang, L.-N. (2019). Intravenous immunoglobulins for alzheimer’s disease and mild cognitive impairment due to alzheimer’s disease: a systematic review with meta-analysis. Expert Rev. Neurother. 19 (6), 475–480. doi: 10.1080/14737175.2019.1620106
Liu, H., Wu, H., Zhu, N., Xu, Z., Wang, Y., Qu, Y., et al (2020). Lactoferrin protects against iron dysregulation, oxidative stress, and apoptosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson’s disease in mice. Journal of Neurochemistry 152 (3), 397–415. doi: 10.1111/jnc.14857
Lönnerdal, B. (1994). Lactoferrin receptors in intestinal brush border membranes. Adv. Exp. Med. Biol. 357, 171–175. doi: 10.1007/978-1-4615-2548-6_16
Lönnerdal, B., Jiang, R., Du, X. (2011). Bovine lactoferrin can be taken up by the human intestinal lactoferrin receptor and exert bioactivities. J. Pediatr. Gastroenterol. Nutr. 53 (6), 606–614. doi: 10.1097/MPG.0b013e318230a419
Lu, J., Francis, J. D., Guevara, M. A., Moore, R. E., Chambers, S. A., Doster, R. S., et al. (2021). Antibacterial and anti-biofilm activity of the human breast milk glycoprotein lactoferrin against group b streptococcus. Chembiochem. A Eur. J. Chem. Biol. 22 (12), 2124–2133. doi: 10.1002/cbic.202100016
Lu, J., Salzberg, S. L. (2018). Removing contaminants from databases of draft genomes. PloS Comput. Biol. 14 (6), e1006277. doi: 10.1371/journal.pcbi.1006277
Lu, L., Zheng, X., Wang, S., Tang, C., Zhang, Y., Yao, G., et al. (2020). Anti-aβ agents for mild to moderate alzheimer’s disease: systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 91 (12), 1316–1324. doi: 10.1136/jnnp-2020-323497
Lynge Pedersen, A. M., Belstrøm, D. (2019). The role of natural salivary defences in maintaining a healthy oral microbiota. J. Dentistry 80 Suppl 1, S3–S12. doi: 10.1016/j.jdent.2018.08.010
Maestre, J. R., Bascones, A., Sánchez, P., Matesanz, P., Aguilar, L., Giménez, M. J., et al. (2007). Odontogenic bacteria in periodontal disease and resistance patterns to common antibiotics used as treatment and prophylaxis in odontology in Spain. Rev. Espanola Quimioterapia Publicacion Oficial la Sociedad Espanola Quimioterapia 20 (1), 61–67.
Martande, S. S., Pradeep, A. R., Singh, S. P., Kumari, M., Suke, D. K., Raju, A. P., et al. (2014). Periodontal health condition in patients with alzheimer’s disease. Am. J. Alzheimer’s Dis. Other Dementias 29 (6), 498–502. doi: 10.1177/1533317514549650
Martorell, P., Llopis, S., Gonzalez, N., Ramón, D., Serrano, G., Torrens, A., et al. (2017). A nutritional supplement containing lactoferrin stimulates the immune system, extends lifespan, and reduces amyloid β peptide toxicity in caenorhabditis elegans. Food Sci. Nutr. 5 (2), 255–265. doi: 10.1002/fsn3.388
Meghil, M. M., Cutler, C. W. (2020). Oral microbes and mucosal dendritic cells, “Spark and flame" of local and distant inflammatory diseases. Int. J. Mol. Sci. 21 (5), 1643. doi: 10.3390/ijms21051643
Miklossy, J. (1993). Alzheimer’s disease–a spirochetosis? Neuroreport 4 (7), 841–848. doi: 10.1097/00001756-199307000-00002
Miklossy, J. (2016). Bacterial amyloid and DNA are important constituents of senile plaques: further evidence of the spirochetal and biofilm nature of senile plaques. J. Alzheimer’s Disease: JAD 53 (4), 1459–1473. doi: 10.3233/JAD-160451
Minn, Y. K., Suk, S. H., Park, H., Cheong, J. S., Yang, H., Lee, S., et al. (2013). Tooth loss is associated with brain white matter change and silent infarction among adults without dementia and stroke. J. Korean Med. Sci 28 (6), 929–933. doi: 10.3346/jkms.2013.28.6.929
Miotto, M., Di Rienzo, L., Bò, L., Boffi, A., Ruocco, G., Milanetti, E. (2021). Molecular mechanisms behind anti SARS-CoV-2 action of lactoferrin. Front. Mol. Biosci. 8, 607443. doi: 10.3389/fmolb.2021.607443
Mizuhashi, F., Koide, K., Toya, S., Takahashi, M., Mizuhashi, R., Shimomura, H. (2015). Levels of the antimicrobial proteins lactoferrin and chromogranin in the saliva of individuals with oral dryness. J. Prosthetic Dentistry 113 (1), 35–38. doi: 10.1016/j.prosdent.2013.12.028
Mohamed, W. A., Salama, R. M., Schaalan, M. F. (2019). A pilot study on the effect of lactoferrin on alzheimer’s disease pathological sequelae: impact of the p-Akt/PTEN pathway. Biomed. Pharmacother. = Biomed. Pharmacother. 111, 714–723. doi: 10.1016/j.biopha.2018.12.118
Mohanty, R., Asopa, S. J., Joseph, M. D., Singh, B., Rajguru, J. P., Saidath, K., et al. (2019). Red complex: polymicrobial conglomerate in oral flora: a review. J. Family Med. Primary Care 8 (11), 3480–3486. doi: 4103/jfmpc.jfmpc_759_19
Morita, Y., Ishikawa, K., Nakano, M., Wakabayashi, H., Yamauchi, K., Abe, F., et al. (2017). Effects of lactoferrin and lactoperoxidase-containing food on the oral hygiene status of older individuals: a randomized, double blinded, placebo-controlled clinical trial. Geriatrics Gerontol. Int. 17 (5), 714–721. doi: 10.1111/ggi.12776
Nakano, M., Shimizu, E., Wakabayashi, H., Yamauchi, K., Abe, F. (2016). A randomized, double-blind, crossover, placebo-controlled clinical trial to assess effects of the single ingestion of a tablet containing lactoferrin, lactoperoxidase, and glucose oxidase on oral malodor. BMC Oral. Health 16, 37. doi: 10.1186/s12903-016-0199-7
Nakano, M., Wakabayashi, H., Sugahara, H., Odamaki, T., Yamauchi, K., Abe, F., et al. (2017). Effects of lactoferrin and lactoperoxidase-containing food on the oral microbiota of older individuals. Microbiol. Immunol. 61 (10), 416–426. doi: 10.1111/1348-0421.12537
Nakano, M., Yoshida, A., Wakabayashi, H., Tanaka, M., Yamauchi, K., Abe, F., et al. (2019). Effect of tablets containing lactoferrin and lactoperoxidase on gingival health in adults: a randomized, double-blind, placebo-controlled clinical trial. J. Periodontal. Res. 54 (6), 702–708. doi: 10.1111/jre.12679
Naorungroj, S., Schoenbach, V. J., Beck, J., Mosley, T. H., Gottesman, R. F., Alonso, A., et al. (2013). Cross-sectional associations of oral health measures with cognitive function in late middle-aged adults a community-based study. J. Am. Dental Assoc 144 (12), 1362–71.
Nara, P. L., Sindelar, D., Penn, M. S., Potempa, J., Griffin, W. S. T. (2021). Porphyromonas gingivalis outer membrane vesicles as the major driver of and explanation for neuropathogenesis, the cholinergic hypothesis, iron dyshomeostasis, and salivary lactoferrin in alzheimer’s disease. J. Alzheimer’s Disease: JAD 82 (4), 1417–1450. doi: 10.3233/JAD-210448
Nie, R., Wu, Z., Ni, J., Zeng, F., Yu, W., Zhang, Y., et al. (2019). Porphyromonas gingivalis infection induces amyloid-β accumulation in Monocytes/Macrophages. J. Alzheimer’s Disease: JAD 72 (2), 479–494. doi: 10.3233/JAD-190298
Noble, J. M., Borrell, L. N., Papapanou, P. N., Elkind, M. S. V., Scarmeas, N., Wright, C. B. (2009). Periodontitis is associated with cognitive impairment among older adults: analysis of NHANES-III. J. Neurol. Neurosurg. Psychiatry 80 (11), 1206–11. doi: 10.1136/jnnp.2009.174029
Noble, J. M., Scarmeas, N., Celenti, R. S., Elkind, M. S. V., Wright, C. B., Schupf, N., et al. (2014). Serum IgG antibody levels to periodontal microbiota are associated with incident alzheimer disease. PloS One 9 (12), e114959. doi: 10.1371/journal.pone.0114959
Okamoto, N., Morikawa, M., Tomioka, K., Yanagi, M., Amano, N., Kurumatani, N. (2015). Association between tooth loss and the development of mild memory impairment in the elderly: the fujiwara-kyo study. J. Alzheimer’s Disease. doi: 10.3233/JAD-141665
Olsen, I. (2021). Porphyromonas gingivalis may seek the alzheimer’s disease brain to acquire iron from its surplus. J. Alzheimer’s Dis. Rep. 5 (1), 79–86. doi: 10.3233/ADR-200272
Olsen, I., Singhrao, S. K. (2020). Low levels of salivary lactoferrin may affect oral dysbiosis and contribute to alzheimer’s disease: a hypothesis. Med. Hypotheses 146, 110393. doi: 10.1016/j.mehy.2020.110393
Ouhara, K., Savitri, I. J., Fujita, T., Kittaka, M., Kajiya, M., Iwata, T., et al. (2014). miR-584 expressed in human gingival epithelial cells is induced by porphyromonas gingivalis stimulation and regulates interleukin-8 production via lactoferrin receptor. J. Periodontol. 85 (6), e198–e204. doi: 10.1902/jop.2013.130335
Paganini-Hill, A., White, S. C., Atchison, K. A. (2012). Dentition, dental health habits, and dementia: the leisure world cohort study. J. Am. Geriatrics Society 60 (8), 1556–63. doi: 10.1111/j.1532-5415.2012.04064.x
Paraskevas, S., Huizinga, J. D., Loos, B. G. (2008). A systematic review and meta-analyses on c-reactive protein in relation to periodontitis. J. Clin. Periodontol. 35 (4), 277–290. doi: 10.1111/j.1600-051X.2007.01173.x
Park, H., Suk, S. H., Cheong, J. S., Lee, H. S., Chang, H., Do, S. Y., et al. (2013). Tooth loss may predict poor cognitive function in community-dwelling adults without dementia or stroke: the PRESENT project. J. Korean Med. Sci. 28 (10), 1518–21. doi: 10.3346/jkms.2013.28.10.1518
Passoja, A., Puijola, I., Knuuttila, M., Niemela, O., Karttunen, R., Raunio, T., et al. (2010). Serum levels of interleukin-10 and tumour necrosis factor-alpha in chronic periodontitis. J. Clin. Periodontol. 37 (10), 881–887. doi: 10.1111/j.1600-051X.2010.01602.x
Petersen, C., Round, J. L. (2014). Defining dysbiosis and its influence on host immunity and disease. Cell. Microbiol. 16 (7), 1024–1033. doi: 10.1111/cmi.12308
Phillips, C. M., Chen, L.-W., Heude, B., Bernard, J. Y., Harvey, N. C., Duijts, L., et al. (2019). Dietary inflammatory index and non-communicable disease risk: a narrative review. Nutrients 11 (8), 1873. doi: 10.3390/nu11081873
Puddu, P., Latorre, D., Carollo, M., Catizone, A., Ricci, G., Valenti, P., et al. (2011). Bovine lactoferrin counteracts toll-like receptor mediated activation signals in antigen presenting cells. PloS One 6 (7), e22504. doi: 10.1371/journal.pone.0022504
Ranjan, R., Rout, M., Mishra, M., Kore, S. A. (2019). Tooth loss and dementia: an oro-neural connection. A cross-sectional study J. Indian Soc. Periodontol. 23 (2), 158–162. doi: 10.4103/jisp.jisp_430_18
Reseco, L., Atienza, M., Fernandez-Alvarez, M., Carro, E., Cantero, J. L. (2021). Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging. Alzheimer’s Res. Ther. 13 (1), 150. doi: 10.1186/s13195-021-00891-8
Reyes Ortiz, C. A., Luque, J. S., Eriksson, C. K., Soto, L. (2013). Self-reported tooth loss and cognitive function: data from the Hispanic established populations for epidemiologic studies of the elderly (Hispanic EPESE). Colombia Medica 44 (3), 139–45. doi: 10.25100/cm.v44i3.1248
Riviere, G. R., Riviere, K. H., Smith, K. S. (2002). Molecular and immunological evidence of oral treponema in the human brain and their association with alzheimer’s disease. Oral. Microbiol. Immunol. 17 (2), 113–118. doi: 10.1046/j.0902-0055.2001.00100.x
Rosa, L., Lepanto, M. S., Cutone, A., Ianiro, G., Pernarella, S., Sangermano, R., et al. (2021). Lactoferrin and oral pathologies: a therapeutic treatment. Biochem. Cell Biol. = Biochimie Biologie Cellulaire 99 (1), 81–90. doi: 10.1139/bcb-2020-0052
Salter, S. J., Cox, M. J., Turek, E. M., Calus, S. T., Cookson, W. O., Moffatt, M. F., et al. (2014). Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 12, 87. doi: 10.1186/s12915-014-0087-z
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., et al. (2011). Metagenomic biomarker discovery and explanation. Genome Biol. 12 (6), R60. doi: 10.1186/gb-2011-12-6-r60
Sengoku, R. (2020). Aging and alzheimer’s disease pathology. Neuropathology 40 (1), 22–29. doi: 10.1111/neup.12626
Shi, Y., Kong, W., Nakayama, K. (2000). Human lactoferrin binds and removes the hemoglobin receptor protein of the periodontopathogen porphyromonas gingivalis. J. Biol. Chem. 275 (39), 30002–30008. doi: 10.1074/jbc.M001518200
Shimizu, E., Kobayashi, T., Wakabayashi, H., Yamauchi, K., Iwatsuki, K., Yoshie, H. (2011). Effects of orally administered lactoferrin and lactoperoxidase-containing tablets on clinical and bacteriological profiles in chronic periodontitis patients. Int. J. Dentistry 2011, 405139. doi: 10.1155/2011/405139
Shin, K., Yaegaki, K., Murata, T., Ii, H., Tanaka, T., Aoyama, I., et al. (2011). Effects of a composition containing lactoferrin and lactoperoxidase on oral malodor and salivary bacteria: a randomized, double-blind, crossover, placebo-controlled clinical trial. Clin. Oral. Investigations 15 (4), 485–493. doi: 10.1007/s00784-010-0422-x
Smith, M. A., Zhu, X., Tabaton, M., Liu, G., McKeel, D. W. J., Cohen, M. L., et al. (2010). Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimer’s Disease: JAD 19 (1), 363–372. doi: 10.3233/JAD-2010-1239
Soukka, T., Tenovuo, J., Rundegren, J. (1993). Agglutination of streptococcus mutans serotype c cells but inhibition of porphyromonas gingivalis autoaggregation by human lactoferrin. Arch. Oral. Biol. 38 (3), 227–232. doi: 10.1016/0003-9969(93)90032-H
Spratt, D. A., Weightman, A. J., Wade, W. G. (1999). Diversity of oral asaccharolytic eubacterium species in periodontitis–identification of novel phylotypes representing uncultivated taxa. Oral. Microbiol. Immunol. 14 (1), 56–59. doi: 10.1034/j.1399-302X.1999.140107.x
Stein, P. S., Desrosiers, M., Donegan, S. J., Yepes, J. F., Kryscio, R. J. (2007). Tooth loss, dementia and neuropathology in the nun study. J. Am. Dental Assoc 138 (10), 1314–22. doi: 10.14219/jada.archive.2007.0046
Steinegger, M., Salzberg, S. L. (2020). Terminating contamination: large-scale search identifies more than 2,000,000 contaminated entries in GenBank. Genome Biol. 21 (1), 115. doi: 10.1186/s13059-020-02023-1
Stewart, R., Stenman, U., Hakeberg, M., Hägglin, C., Gustafson, D., Skoog, I. (2015). Associations between oral health and risk of dementia in a 37-year follow-up study: the prospective population study of women in gothenburg. J. Am. Geriatrics Society 63 (1), 100–5. doi: 10.1111/jgs.13194
Suárez Moya, A. (2017). [Microbiome and next generation sequencing]. Rev. espanola quimioterapia: publicacion oficial la Sociedad Espanola Quimioterapia 30 (5), 305–311.
Sudhakara, P., Gupta, A., Bhardwaj, A., Wilson, A. (2018). Oral dysbiotic communities and their implications in systemic diseases. Dentistry J. 6 (2), 10. doi: 10.3390/dj6020010
Sung, C. E., Huang, R. Y., Cheng, W. C., Kao, T. W., Chen, W. L. (2019). Association between periodontitis and cognitive impairment: analysis of national health and nutrition examination survey (NHANES) III. J. Clin. Periodontol. 46 (8), 790–798. doi: 10.1111/jcpe.13155
Sureda, A., Daglia, M., Argüelles Castilla, S., Sanadgol, N., Fazel Nabavi, S., Khan, H., et al. (2020). “Oral microbiota and alzheimer’s disease: do all roads lead to Rome?,” in Pharmacol Res 151, 104582. doi: 10.1016/j.phrs.2019.104582
Taati Moghadam, M., Amirmozafari, N., Mojtahedi, A., Bakhshayesh, B., Shariati, A., Masjedian Jazi, F. (2022). Association of perturbation of oral bacterial with incident of alzheimer’s disease: a pilot study. J. Clin. Lab. Anal. 36 (7), e24483. doi: 10.1002/jcla.24483
Tadjoedin, F. M., Masulili, S. L. C., Rizal, M. I., Kusdhany, L. S., Turana, Y., Ismail, R. I., et al. (2022). The red and orange complex subgingival microbiome of cognitive impairment and cognitively normal elderly with periodontitis. Geriatrics (Basel Switzerland) 7 (1), 12. doi: 10.3390/geriatrics7010012
Takata, Y., Ansai, T., Soh, I., Sonoki, K., Awano, S., Hamasaki, T., et al. (2009). Cognitive function and number of teeth in a community-dwelling elderly population without dementia. J. Oral. Rehabilitation 36 (11), 808–13. doi: 10.1111/j.1365-2842.2009.01998.x
Takeuchi, K., Ohara, T., Furuta, M., Takeshita, T., Shibata, Y., Hata, J., et al. (2017). Tooth loss and risk of dementia in the community: the hisayama study. J. Am. Geriatrics Soc. 65 (5), e95–e100. doi: 10.1111/jgs.14791
Teixeira, F. B., Saito, M. T., Matheus, F. C., Prediger, R. D., Yamada, E. S., Maia, C. S. F., et al. (2017). Periodontitis and alzheimer’s disease: a possible comorbidity between oral chronic inflammatory condition and neuroinflammation. Front. Aging Neurosci 9, 327. doi: 10.3389/fnagi.2017.00327
Tiisanoja, A., Syrjälä, A. M., Tertsonen, M., Komulainen, K., Pesonen, P., Knuuttila, M., et al. (2019). Oral diseases and inflammatory burden and alzheimer’s disease among subjects aged 75 years or older. Special Care Dentistry 39 (2), 158–165. doi: 10.1111/scd.12357
Tonsekar, P. P., Jiang, S. S., Yue, G. (2017). Periodontal disease, tooth loss and dementia: is there a link? a systematic review. Gerodontology 34 (2), 151–163. doi: 10.1111/ger.12261
Tsatsanis, A., McCorkindale, A. N., Wong, B. X., Patrick, E., Ryan, T. M., Evans, R. W., et al. (2021). The acute phase protein lactoferrin is a key feature of alzheimer’s disease and predictor of aβ burden through induction of APP amyloidogenic processing. Mol. Psychiatry 26 (10), 5516–5531. doi: 10.1038/s41380-021-01248-1
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., et al. (2022). Lecanemab in early alzheimer’s disease. New Engl. J. Med 388 (1), 9–21. doi: 10.1056/NEJMoa2212948
Varatharaj, A., Galea, I. (2017). The blood-brain barrier in systemic inflammation. Brain Behavior Immun. 60, 1–12. doi: 10.1016/j.bbi.2016.03.010
Wakabayashi, H., Yamauchi, K., Kobayashi, T., Yaeshima, T., Iwatsuki, K., Yoshie, H. (2009). Inhibitory effects of lactoferrin on growth and biofilm formation of porphyromonas gingivalis and prevotella intermedia. Antimicrobial. Agents Chemother. 53 (8), 3308–3316. doi: 10.1128/AAC.01688-08
Wang, B., Timilsena, Y. P., Blanch, E., Adhikari, B. (2019). Lactoferrin: structure, function, denaturation and digestion. Crit. Rev. Food Sci. Nutr. 59 (4), 580–596. doi: 10.1080/10408398.2017.1381583
Watts, A., Crimmins, E. M., Gatz, M. (2008). Inflammation as a potential mediator for the association between periodontal disease and alzheimer’s disease. Neuropsychiatr. Dis. Treat 4 (5), 865–876. doi: 10.2147/ndt.s3610
Whitchurch, C. B., Tolker-Nielsen, T., Ragas, P. C., Mattick, J. S. (2002). Extracellular DNA required for bacterial biofilm formation. Sci. (New York N.Y.) 295 (5559), 1487. doi: 10.1126/science.295.5559.1487
Wilkins, H. M., Swerdlow, R. H. (2016). Relationships between mitochondria and neuroinflammation: implications for alzheimer’s disease. Curr. Topics Medicinal Chem. 16 (8), 849–857. doi: 10.2174/1568026615666150827095102
Wu, B., Fillenbaum, G. G., Plassman, B. L., Guo, L. (2016). Association between oral health and cognitive status: a systematic review. J. Am. Geriatrics Society 64 (4), 739–51. doi: 10.1111/jgs.14036
Wu, Y.-F., Lee, W.-F., Salamanca, E., Yao, W.-L., Su, J.-N., Wang, S.-Y., et al. (2021). Oral microbiota changes in elderly patients, an indicator of alzheimer’s disease. Int. J. Environ. Res. Public Health 18 (8), 4211. doi: 10.3390/ijerph18084211
Wu, Z., Ni, J., Liu, Y., Teeling, J. L., Takayama, F., Collcutt, A., et al. (2017). Cathepsin b plays a critical role in inducing alzheimer’s disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from porphyromonas gingivalis in mice. Brain Behavior Immun. 65, 350–361. doi: 10.1016/j.bbi.2017.06.002
Xu, F., Laguna, L., Sarkar, A. (2019). Aging-related changes in quantity and quality of saliva: where do we stand in our understanding? J. Texture Stud. 50 (1), 27–35. doi: 10.1111/jtxs.12356
Yamamoto, T., Kondo, K., Hirai, H., Nakade, M., Aida, J., Hirata, Y. (2012). Association between self-reported dental health status and onset of dementia: a 4-year prospective cohort study of older Japanese adults from the aichi gerontological evaluation study (AGES) project. Psychosomatic Med 74 (3), 241–8. doi: 10.1097/PSY.0b013e318246dffb
Yang, A., Du, L., Gao, W., Liu, B., Chen, Y., Wang, Y., et al. (2022). Associations of cortical iron accumulation with cognition and cerebral atrophy in alzheimer’s disease. Quantitative Imaging Med. Surg. 12 (9), 4570–4586. doi: 10.21037/qims-22-7
Yang, B., Tao, B., Yin, Q., Chai, Z., Xu, L., Zhao, Q., et al. (2021). Associations between oral health status, perceived stress, and neuropsychiatric symptoms among community individuals with alzheimer’s disease: a mediation analysis. Front. Aging Neurosci. 13, 801209. doi: 10.3389/fnagi.2021.801209
Yoo, J. J., Yoon, J. H., Kang, M. J., Kim, M., Oh, N. (2019). The effect of missing teeth on dementia in older people: a nationwide population-based cohort study in south Korea. BMC Oral. Health 19 (1), 61. doi: 10.1186/s12903-019-0750-4
Yost, S., Duran-Pinedo, A. E., Teles, R., Krishnan, K., Frias-Lopez, J. (2015). Functional signatures of oral dysbiosis during periodontitis progression revealed by microbial metatranscriptome analysis. Genome Med. 7 (1), 27. doi: 10.1186/s13073-015-0153-3
Zeng, H., Chan, Y., Gao, W., Leung, W. K., Watt, R. M. (2021). Diversity of treponema denticola and other oral treponeme lineages in subjects with periodontitis and gingivitis. Microbiol. Spectr. 9 (2), e0070121. doi: 10.1128/Spectrum.00701-21
Zhang, Y., Qi, Y., Lo, E. C. M., McGrath, C., Mei, M. L., Dai, R. (2021). Using next-generation sequencing to detect oral microbiome change following periodontal interventions: a systematic review. Oral. Dis. 27 (5), 1073–1089. doi: 10.1111/odi.13405
Zhang, S., Yu, N., Arce, R. M. (2020). Periodontal inflammation: integrating genes and dysbiosis. Periodontology 2000 82 (1), 129–142. doi: 10.1111/prd.12267
Keywords: oral microbiome, oral dysbiosis, periodontal disease, Porphyromonas gingivalis, next-generation sequencing (NGS), false-positive detection, lactoferrin
Citation: Weber C, Dilthey A and Finzer P (2023) The role of microbiome-host interactions in the development of Alzheimer´s disease. Front. Cell. Infect. Microbiol. 13:1151021. doi: 10.3389/fcimb.2023.1151021
Received: 25 January 2023; Accepted: 16 May 2023;
Published: 02 June 2023.
Edited by:
Mohamed M. H. Abdelbary, University Hospital RWTH Aachen, GermanyReviewed by:
Gena D. Tribble, University of Texas Health Science Center at Houston, United StatesAli Al-Ahmad, University of Freiburg Medical Center, Germany
Copyright © 2023 Weber, Dilthey and Finzer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Patrick Finzer, cGF0cmljay5maW56ZXJAdW5pLWR1ZXNzZWxkb3JmLmRl
†These authors share senior authorship